• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

AIM: To find an effective symptomatic treatment for osteogenesis imperfecta (OI). METHODS: In a prospective observational study disodium pamidronate (APD) was given as monthly intravenous infusions to 28 children and adolescents (aged 0.6-18 years) with severe OI or a milder form of the disease, but with spinal compression fractures. RESULTS: During treatment for 2-9 years, dual energy x ray absorptiometry measurements of the total body and of the lumbar spine showed a gradual increase in bone density. All bone metabolism variables in serum (alkaline phosphatase, osteocalcin, procollagen 1 C-terminal peptide, collagen 1 teleopeptide) and urine (deoxypyridinoline) indicated that there was a decrease in bone turnover. All patients experienced beneficial effects and the younger patients reported a major improvement in wellbeing, pain, and mobility without significant side effects. Vertebral remodelling was also seen. CONCLUSIONS: APD seems to be an efficient symptomatic treatment for children and adolescents with OI.

Pubmed ID: 11970931

Authors

  • Aström E
  • Söderhäll S

Journal

Archives of disease in childhood

Publication Data

May 23, 2002

Associated Grants

None

Mesh Terms

  • Absorptiometry, Photon
  • Adolescent
  • Biological Markers
  • Bone Density
  • Bone Remodeling
  • Child
  • Child, Preschool
  • Diphosphonates
  • Fractures, Spontaneous
  • Health Status
  • Humans
  • Infant
  • Infusions, Intravenous
  • Long-Term Care
  • Osteogenesis Imperfecta
  • Pain
  • Prospective Studies
  • Recurrence
  • Spinal Cord Compression
  • Treatment Outcome